Himil Mahadevia

Articles by Himil Mahadevia

70 Real-World Outcomes and Toxicity of Trastuzumab Deruxtecan in Older Adults With Breast Cancer: A Mayo Clinic Multi-Site Analysis

ByHimil Mahadevia,Paul Borgman,Madhavi Nayyar,Sowmya Guna,Sumeet Yadav,Yajur Arya,Arshi Syal,Nathaniel Wiest,Rohit Rao

June 13th 2026

Real-world study shows T-DXd benefits older metastatic breast cancer patients, but higher ILD risk and toxicity-driven discontinuation demand close monitoring, especially in octogenarians.

Latest Updated Articles

Himil Mahadevia

Articles by Himil Mahadevia

70 Real-World Outcomes and Toxicity of Trastuzumab Deruxtecan in Older Adults With Breast Cancer: A Mayo Clinic Multi-Site Analysis

Latest Updated Articles

Trending on CancerNetwork

Daraxonrasib/Vopimetostat Yields Stunning Response Rate in MTAP-del Pancreatic Cancer

FDA Approves Adjuvant Belzutifan/Pembrolizumab in Clear Cell RCC Post Nephrectomy

Investigators Halt Phase 3 Trial of Sacituzumab Govitecan Combo in NSCLC

Quadruplet Combo Appears Effective in High-Risk Smoldering Multiple Myeloma

Anbenitamab Regimen Meets Phase 3 End Points in HER2+ Breast Cancer